25 results on '"Schubert, Maria-Luisa"'
Search Results
2. Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
3. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
4. Extracorporeal photopheresis as a promising strategy for the treatment of GvHD after CAR-T cell therapy
5. Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study
6. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
7. Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial
8. CD22 CAR T-cell therapy: new hope for patients with large B-cell lymphoma.
9. Comparison of single copy gene‑based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19‑directed CAR T cells in treated patients
10. Response to extracorporeal photopheresis therapy of patients with steroid-refractory/-resistant GvHD is associated with up-regulation of Th22 cells and Tfh cells
11. Response to Vaccination with Sars-CoV2 Vaccines in Patients Post Allogeneic Hematopoietic Cell Transplantation
12. Humoral Responses and Chronic GVHD Exacerbation after COVID-19 Vaccination Post Allogeneic Stem Cell Transplantation
13. HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma
14. CD33‐directed immunotherapy with third‐generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact andCD33‐edited acute myeloid leukemia and hematopoietic stem and progenitor cells
15. Sensitivity and Specificity of CD19.CAR-T Cell Detection by Flow Cytometry and PCR
16. Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis
17. Third-Generation Chimeric Antigen Receptor (CAR) T Cells in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) - Results from the Heidelberg Trial 1 (HD-CAR-1 trial)
18. CD19.CAR-T Cell Analysis Using Flow Cytometry and PCR
19. The Decrease of Anti-CD3 Antibody Concentration Improved the Cytotoxicity of Chimeric Antigen Receptor (CAR) T Cells in the Treatment of Chronic Lymphoblastic Leukemia (CLL)
20. Six-Month Follow-up for Infectious Complications after Lymphodepletion and Application of CD19-Chimeric Antigen Receptor T (CAR-T) Cell Therapy
21. Th22 and Tfh Cell Elevation Is Associated with Clinical Response of Photopheresis Therapy in Patients with Steroid-Refractory/ Resistant Graft-Versus-Host Disease (GvHD)
22. Graft-Versus-Host Disease after Anti-CD19 Chimeric Antigen Receptor T-Cell Infusion Post Allogeneic Hematopoietic Cell Transplantation: A Transplant Complications and Paediatric Disease Working Parties EBMT Joint Study
23. CD33‐directed immunotherapy with third‐generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33‐edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
24. 473 - Response to Vaccination with Sars-CoV2 Vaccines in Patients Post Allogeneic Hematopoietic Cell Transplantation
25. High Body Mass Index Is Associated with Favorable Outcome in Younger Patients Receiving CD19 CAR T-Cell Therapy for B-Cell Lymphoma: A Retrospective Study from the EBMT Transplant Complications Working Party
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.